Evidence map›Paper›PMID 40496555›Full record

ArticleFrontiers in endocrinology2025

AI-based multimodal prediction of lymph node metastasis and capsular invasion in cT1N0M0 papillary thyroid carcinoma.

Xiaowei Peng, Peng Wu, Wu Li, Tao Ou-Yang, Shi Chu Tang, Shiwei Zhou, Hui Li, Xiaohua Song, Yulong Tang

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaowei Peng *Department of Thyroid Surgery, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Peng Wu *Department of Thyroid Surgery, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Wu LiDepartment of Thyroid Surgery, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Tao Ou-YangDepartment of Medical Ultrasound, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Shi Chu TangDepartment of Medical Ultrasound, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Shiwei ZhouDepartment of Thyroid Surgery, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Hui LiDepartment of Thyroid Surgery, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Xiaohua SongDepartment of Thyroid Surgery, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yulong TangDepartment of Thyroid Surgery, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate preoperative evaluation of cT1N0M0 papillary thyroid carcinoma (PTC) is essential for guiding appropriate treatment strategies. Although ultrasound is widely used for clinical staging, it has limitations in detecting lymph node metastasis (LNM) and capsular invasion (CI), which may lead to misclassification of high-risk patients. Such undetected risks pose safety concerns for those undergoing radiofrequency ablation. This study aimed to develop an artificial intelligence (AI)-assisted predictive model that integrates ultrasound radiomics and deep learning features to improve the identification of LNM and CI, thereby enhancing risk stratification and optimizing treatment strategies for cT1N0M0 PTC patients. Methods: A total of 203 PTC patients were divided into high-risk (CI or LNM) and low-risk groups, with 142 assigned to the training set and 61 to the internal test set. Regions of interest delineation was performed using ITK-Snap. Radiomic features were extracted with PyRadiomics, and embedding features were obtained through the Vision Transformer (ViT) model. Risk-related features were selected using least absolute shrinkage and selection operator (LASSO), variance thresholding, and recursive feature elimination (RFE). Single-modal and multimodal models were developed using feature-level and decision-level fusion. Feature importance was assessed using Shapley Additive exPlanations (SHAP). Model performance was evaluated using recall, accuracy, and area under curve (AUC). Results: Among 1,001 radiomics features, 47 were selected via LASSO and RFE, and 15 relevant features from 768 ViT features. In the internal test set, NeuralNet models based on radiomics and 2D deep learning achieved AUCs of 0.756 and 0.708, respectively, and 0.829 and 0.840 in the training set. The multimodal RandomForest model outperformed single-modality models, with an AUC of 0.763 in the test set and 0.992 in the training set. Decision-level fusion models, such as DLRad_LF_Avg and DLRad_LF_Max, improved the external test set AUC to 0.843. SHAP analysis identified key features linked to tumor heterogeneity. Conclusion: The multimodal AI model effectively predicts high-risk cT1N0M0 PTC, outperforming single-modality models and aiding clinical decision-making.

Indexed as

Artificial IntelligenceLymphatic MetastasisThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisRetrospective StudiesUltrasonographyartificial intelligencepapillary thyroid cancerprediction modelrisk stratificationultrasound radiomics

Identifiers

PMID40496555
PMCPMC12148903

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.